COCH predicts survival and adjuvant TACE response in patients with HCC.
The aim of the present study was to measure the expression of Cochlin (COCH) and analyze its association with survival, recurrence and the benefits from adjuvant transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) following hepatectomy. Patients with high COCH expression levels had a poorer prognosis in terms of overall and disease-free survival rate compared with those with low COCH expression levels. Further analysis revealed that patients with low COCH expression who received TACE experienced markedly lower early recurrence rates compared with those who did not receive TACE. However, patients with high COCH expression with and without adjuvant TACE after resection experienced no difference in disease recurrence rates. The expression of COCH was found to be associated with hepatitis B virus infection, portal vein tumor thrombosis and Barcelona Clinic Liver Cancer stage in HCC. Therefore, the findings of the present study indicated that clinical detection of COCH expression may help estimate the prognosis of patients with HCC, as well as determine whether to administer TACE after surgery to prevent recurrence.
['Wang|Chen|C|', 'Ding|Zhi-Wen|ZW|', 'Zheng|Cheng-Gang|CG|', 'Wang|Siyuan|S|', 'Li|Zhi-Heng|ZH|', 'Zhang|Zi-Mu|ZM|', 'Pan|Jian|J|', 'Wang|Jian|J|', 'Yang|Chun|C|']
survival cochlin recurrence transarterial chemoembolization hepatocellular carcinoma